Market

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Read More

Related Posts

Social Security Administration announces ‘massive’ reorganization, ‘significant’ job cuts

Social Security Administration announces ‘massive’ reor...

Nvidia’s stock is in a funk. Earnings didn’t help, but here’s what could.

Nvidia’s stock is in a funk. Earnings didn’t help, but ...

Canada watchdog probing X's use of personal data in AI models' training

Canada watchdog probing X's use of personal data in AI ...

Autodesk says it’s cutting 9% of its workforce, and shares rise

Autodesk says it’s cutting 9% of its workforce, and sha...

Factbox-Key economic targets expected to be approved by China's parliament

Factbox-Key economic targets expected to be approved by...

Virgin Galactic’s new spacecraft looms large as company eyes future profitability

Virgin Galactic’s new spacecraft looms large as company...